Dadun Dadun cabecera universidad cabecera biblioteca
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma
Authors: Garcia-Sanz, R. (R.)
Hernandez, J. (J.M.)
Sureda, A. (Anna)
Garcia-Laraña, J. (J.)
Prosper, F. (Felipe)
Alegre, A. (A.)
Barez, A. (A.)
Mateos, M.V. (María Victoria)
San-Miguel, J.F. (Jesús F.)
Keywords: Multiple myeloma
Pegylated liposomal doxorubicin
Melphalan
Prednisone
First line
Chemotherapy
Newly diagnosed
Untreated
Issue Date: 2006
Publisher: Wiley-Blackwell
Publisher version: http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291099-1069
ISSN: 0278-0232
Citation: García-Sanz, R., Hernández, J. M., Sureda, A., García-Laraña, J. et al. Hematol. Oncol. 2006; 24 (4): 205-211
Abstract
Melphalan&Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high-dose therapy. Here, we report the results of a phase I–II study to evaluate the feasibility and efficacy of the association of PLDto the conventionalMP regimen during the first six cycles of the front-line therapy for untreatedMMpatients older than 70. Thirty patients were included in the study with a median age of 77 years (71–84) and a M/F ratio of 17/13. The phase I of the study demonstrated that the maximum tolerable dose of PLD in this setting was 30mg/m2, so itwas the final dose evaluated in the study. Twenty-nine patients were valuable for response, which was: complete in 4 (14%) partial in 15 (52%) minor/ no changes in 7 (24%) and progressive in 3 (10%). The median progression free survival (PFS) was 24 months. The median overall survival (OS) has not been reached yet, with a 3-year probability for OS and PFS of 52 and 37%, respectively. Haematological toxicity was frequent but usually weak/moderate (grades 1&2 of theWHOscale) and itwas resolved only with dose delays. Infection was a relatively frequent event (30%of patients), but only in 4 cases it was of grade 3. No cases of palmar-plantar erythrodysesthesia were observed. In conclusion, pegylated liposomal doxorubicin can be safely added to the other chemotherapeutic drugs in the treatment of elderly MM patients, which can be very useful for patients in whomnovel agents are not tolerated or inefficient.
Permanent link: http://hdl.handle.net/10171/17457
Appears in Collections:DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.